Zhang Z - Search Results

1

Combination of STING agonist and CXCR3 antagonist disrupts immune tolerance to overcome anti-PD-L1 resistance in lung adenocarcinoma under oxidative stress.

Zhu L, Gao H, Huang S, Cao T, Zhai X, Hu J, Wang T, Dong J, Liu Z, Chen J, Liu J, Zhang Z, Zhou Q. Zhu L, et al. Among authors: zhang z. Gene. 2023 Jan 30;851:146962. doi: 10.1016/j.gene.2022.146962. Epub 2022 Oct 19. Gene. 2023. PMID: 36272651

2

Growth inhibition of the pulmonary metastatic tumors by systemic delivery of the p27 kip1 gene using lyophilized lipid-polycation-DNA complexes.

Sun X, Zhang HW, Zhang ZR. Sun X, et al. J Gene Med. 2009 Jun;11(6):535-44. doi: 10.1002/jgm.1322. J Gene Med. 2009. PMID: 19326369

3

A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma.

Zhou Q, Sun X, Zeng L, Liu J, Zhang Z. Zhou Q, et al. Among authors: zhang z. Nanomedicine. 2009 Dec;5(4):419-23. doi: 10.1016/j.nano.2009.01.009. Epub 2009 Feb 13. Nanomedicine. 2009. PMID: 19523421 Clinical Trial.

4

Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses.

Zeng Q, Jiang H, Wang T, Zhang Z, Gong T, Sun X. Zeng Q, et al. Among authors: zhang z. J Control Release. 2015 Feb 28;200:1-12. doi: 10.1016/j.jconrel.2014.12.024. Epub 2014 Dec 23. J Control Release. 2015. PMID: 25540903

5

A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy.

Wang L , Qu M , Huang S , Fu Y , Yang L , He S , Li L , Zhang Z , Lin Q , Zhang L . Wang L , et al. Among authors: zhang l, zhang z. Nanoscale. 2018 Jul 19;10(28):13673-13683. doi: 10.1039/c8nr03297a. Nanoscale. 2018. PMID: 29987301

6

Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.

Li M, Yang Y, Xu C, Wei J, Liu Y, Cun X, Yu Q, Tang X, Yin S, Zhang Z, He Q. Li M, et al. Among authors: zhang z. AAPS J. 2019 Jan 11;21(2):18. doi: 10.1208/s12248-018-0289-3. AAPS J. 2019. PMID: 30635795

7

Target delivering paclitaxel by ferritin heavy chain nanocages for glioma treatment.

Liu W, Lin Q, Fu Y, Huang S, Guo C, Li L, Wang L, Zhang Z, Zhang L. Liu W, et al. Among authors: zhang l, zhang z. J Control Release. 2020 Jul 10;323:191-202. doi: 10.1016/j.jconrel.2019.12.010. Epub 2019 Dec 12. J Control Release. 2020. PMID: 31838201

8

Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier.

Huang S, Zhang Y, Wang L, Liu W, Xiao L, Lin Q, Gong T, Sun X, He Q, Zhang Z, Zhang L. Huang S, et al. Among authors: zhang l, zhang z, zhang y. J Control Release. 2020 Sep 10;325:10-24. doi: 10.1016/j.jconrel.2020.03.049. Epub 2020 Apr 3. J Control Release. 2020. PMID: 32251770

9

Integrin α₂β₁ Targeting DGEA-Modified Liposomal Doxorubicin Enhances Antitumor Efficacy against Breast Cancer.

Zhou B, Li M, Xu X, Yang L, Ye M, Chen Y, Peng J, Xiao L, Wang L, Huang S, Zhang L, Lin Q, Zhang Z. Zhou B, et al. Among authors: zhang l, zhang z. Mol Pharm. 2021 Jul 5;18(7):2634-2646. doi: 10.1021/acs.molpharmaceut.1c00132. Epub 2021 Jun 16. Mol Pharm. 2021. PMID: 34134485

10

Enhanced anti-metastatic therapy with down-regulation of heparinase expression by ROS-responsive micellar nanoparticles.

Zhang Y, Li Y, Huang S, Zhang H, Lin Q, Gong T, Sun X, Zhang Z, Zhang L. Zhang Y, et al. Among authors: zhang l, zhang z, zhang h. Nanoscale. 2021 Sep 23;13(36):15267-15277. doi: 10.1039/d1nr02964a. Nanoscale. 2021. PMID: 34477185

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

112,243 results

Search Page

Filters